Company Information

    Prevail Therapeutics was founded on January 2017. The company is based in New York, NY, USA . The number of employees in Prevail Therapeutics is less than 50. Prevail therapeutics is a biotechnology company focused on developing novel gene therapies for patients with parkinson s disease.
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Prevail Therapeutics has received 3 rounds of venture funding. The total funding amount is around $129M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Prevail Therapeutics - Blog

                          • Lilly Announces Agreement to Acquire Prevail Therapeutics

                          • Acquisition will establish a gene therapy program at Lilly, anchored by Prevail’s portfolio of neuroscience assets, and will broaden Lilly’s commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ:...The post Lilly Announces Agreement to Acquire Prevail Therapeutics appeared first on Prevail.
                          • Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations

                          • NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the first patient has been dosed in the Phase 1/2 PROCLAIM clinical trial evaluating PR006, an investigational AAV9 gene therapy delivering the GRN gene, for...The post Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations appeared first on Prevail.
                          • Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia

                          • NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the European Commission has granted orphan designation for PR006 for the treatment of frontotemporal dementia (FTD). PR006 is an investigational AAV9 gene therapy delivering the...The post Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia appeared first on Prevail.
                          • Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001

                          • NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark Office (USPTO) on November 17, 2020 issued a composition of matter patent, U.S. Patent No. 10,837,028, with claims directed to the AAV...The post Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001 appeared first on Prevail.
                          • Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

                          • Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Phase 1/2 PROVIDE Trial of PR001 for Type 2 Gaucher Disease and Phase 1/2 PROCLAIM Trial of PR006 for Frontotemporal Dementia with GRN Mutations Expected to Initiate Enrollment in Fourth Quarter of 2020 PR001 Receives U.S. FDA Fast...The post Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights appeared first on Prevail.
                          • Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO

                          • Decision Vindicates Dr. Abeliovich and Confirms Integrity of Prevail’s Intellectual Property NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced a decisive victory in the arbitration proceeding brought in 2019 by Alector Inc. against Prevail’s...The post Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO appeared first on Prevail.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *